The earnings of five listed companies under the pharmaceutical and chemical sectors have increased in the second quarter [October-December period] of FY24, when compared year-on-year.
These companies are – IBN SINA Pharmaceutical Industry, Ambee Pharmaceuticals, Beacon Pharmaceuticals, Beximco Pharmaceuticals, and Renata Ltd.
This information was obtained from the unaudited financial reviews of the companies, published on the Dhaka Stock Exchange (DSE) website on Sunday and Monday.
IBN SINA Pharmaceutical Industry PLC
Drug manufacturer IBN SINA Pharmaceuticals' earnings per share (EPS) stood at Tk 11.92 in the first six months of FY24, compared to Tk 10.53 in the same period last year.
However, the earnings per share during the second quarter of FY24 (October-December) stood at Tk 6.70, against Tk 5.90 for October-December 2022.
Although IBN SINA Pharmaceutical did not disclose any explanation as to why their profits increased at this time, its Company Secretary Kabir Hossain said, “We are getting a lot of income through the natural medicine unit. As a result, our revenue and profits increased.”
IBN SINA Pharmaceutical manufactures drugs such as herbal and Unani medicines. Gazipur is home to its manufacturing facilities.
The company’s net operating cash flow per share (NOCFPS) was Tk 11.05 for the July-December period last year, against Tk 13.92 posted in the July-December segment of 2022. Its net asset value (NAV) per share was Tk 102.59 until December 31 and Tk 96.68 until June 30 last year.
Ambee Pharmaceuticals
Ambee Pharmaceuticals’ earnings per share in the first six months of FY24 stood at Tk 1.20, compared to Tk 0.60 in the same period last year. During this period, the company’s earnings per share increased by nearly 100 per cent.
The company’s earnings per share in the second quarter of FY24 stood at Tk 0.60, against Tk 0.35 recorded in the October-December period of 2022.
NOCFPS was negative Tk 5.61 for the July-December period last year, compared to Tk 7.69 recorded year-on-year. NAV per share was Tk 9.43 as on December 31, 2023 and Tk 9.73 on June 30, 2023.
It has recommended 15 per cent cash dividends for its shareholders for FY23.
Established in 1976, Ambee Pharmaceuticals got listed on the stock market in 1986. It went into operation with modest 17 joint ventured products and is now running in full swing with 76 products.
Beacon Pharmaceuticals
Beacon Pharmaceuticals has posted a 1.22 per cent increase in its earnings in the second quarter that ended on December 31 last year, against the same quarter last year.
Its earnings per share (EPS) stood at Tk 1.65 in the Q2, up from Tk 1.63 recorded in the same period a year earlier. Until December 31, 2022, the company's net asset value (NAV) per share stood at Tk 27.38, against Tk 26.76 until December 31, 2021.
Meanwhile, the company had earnings per share (EPS) of Tk 3.25 in the first six months of FY24.
Renata Ltd
The consolidated earnings per share (EPS) of Renata Ltd, a leading drug manufacturing company in Bangladesh, increased to Tk 7.68 in the first six months of FY24, while the previous FY's EPS for the same period stood at Tk 7.42, show its unaudited financial statements.
Consolidated EPS was Tk 16.57 for the July-December period of 2023, against Tk 18.28 for the July-December period of 2022.
The company’s consolidated net operating cash flow per share (NOCFPS) was Tk 2.80 for the July-December period last year, against negative Tk 2.50 recorded year-on-year. Consolidated NAV per share stood at Tk 277.23 until December 31, and Tk 266.87 until June 30 last year.
The company is involved in the business of manufacturing, marketing, and distributing medicines, nutritional products, and vaccines for humans, along with veterinary medications.
The company started its operations in 1972 as Pfizer (Bangladesh) Ltd. However, in 1993, Pfizer transferred ownership of its operations to local shareholders, and the company name was changed to Renata Ltd.
The drug manufacturer was listed on the stock exchanges in 1979, and its shares are currently stuck on the floor price at Tk 1,217.90 each.
Beximco Pharmaceuticals Ltd
Beximco Pharmaceuticals Ltd, a listed company in the stock market, recently released its unaudited financial report for the second quarter [October-December period] of FY24.
According to company sources, the company's earnings per share (EPS) in the period stood at Tk 3.21, and compared to Tk 2.77 year-on-year.
Besides, the company’s earnings per share (EPS) stood at TK 6.69 in the first six months [July-December period] of FY24, and compared to Tk 6.02 year-on-year.
